Authors
Wenpei Li, Shaoping Jiang, Kun Liu, Zhi Li, Jun Yang, Weimin Liu, Yuanyu Huang, Minghui Yang, Shuai Guo, Shaobo Ruan
Published in
Journal of extracellular biology. Volume 5. Issue 7. Pages e70161. Epub Jun 30, 2026.
Abstract
Temozolomide (TMZ) is a first-line chemotherapeutic agent for the treatment of glioblastoma (GBM), while a majority of patients do not effectively respond to TMZ owing to the multiple resistance mechanisms. In this study, we found that TMZ treatment substantially increased the exosome secretion from GBM cell line. The secreted exosomes from TMZ-treated C6 cells maintained typical physicochemical properties, with only slight fluctuation in expression profile of surface markers compared to untreated cell-derived exosomes. Further investigation revealed that increased expression of p53 might be the predominant reason to promote exosome secretion, potentially through the upregulation of six-transmembrane epithelial antigen of prostate 3 (STEAP3) expression under stress condition. Moreover, we identified that pre-treatment with TMZ-induced exosomes could reduce the sensitivity of C6 cells to TMZ and considered that exosome secretion may serve as a potent TMZ resistance mechanism via enhancing anti-apoptotic ability of GBM cells towards TMZ exposure. Proteomics analysis revealed a strategic mechanism to resist TMZ-induced apoptosis by upregulating exosomal proteins associated with biogenesis, chemoresistance, and therapeutic adaption. This finding revealed a considerable TMZ resistance mechanism and provided a new inspiration for preventing exosome biogenesis to resensitise TMZ cytotoxicity towards GBM.
PMID:
42383157
Bibliographic data and abstract were imported from PubMed on 01 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0